First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials

Jinzhao Zhai1,2 | Jiangyue Lu3 | Zhibo Zhang4 | Yuan Wang5 | Xiaoyan Li1 | Sujie Zhang1 | Shuai Mu1 | Xiaoyu Zhi1,2 | Xiangwei Ge1,2 | Di Lu1,2 | Yi Hu1 | Jinliang Wang1

Abstract
Chemotherapy in combination with immune checkpoint inhibitor (ICI) or bevacizumab has demonstrated a superior effect for non-squamous non-small cell lung cancer (NS-NSCLC). There are still few randomized controlled trials (RCTs) investigating the differences between ICI plus chemotherapy (ICI-chemotherapy) and bevacizumab plus chemotherapy (Bev-chemotherapy) in first-line treatment of NS-NSCLC. We identified RCTs in databases and conference abstracts presented at international conferences by Sep 1, 2021. Bayesian network meta-analysis was performed using randomized effect consistency model to estimate hazard ratio (HR) and odds ratio (OR). The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and grade ≥3 treatment-related adverse events (TRAEs). Fifteen RCTs (17 articles) of 6561 advanced NS-NSCLC patients receiving ICI-chemotherapy, Bev-chemotherapy, or chemotherapy at first-line were eligible for analysis. NMA results showed that first-line ICI-chemotherapy prolonged OS (HR 0.79, 0.66–0.94) in patients with advanced NS-NSCLC compared with Bev-chemotherapy, while no differences were in PFS, ORR, and grade ≥3 TRAEs (p > 0.05). Ranking plots suggested that ICI-chemotherapy had the most probability to offer the best OS (probability 0.993), PFS (probability 0.658), and ORR (probability 0.565), and Bev-chemotherapy had the most risks of grade ≥3 TRAEs (probability 0.833). Therefore, our findings showed that first-line ICI-chemotherapy was associated with better OS than Bev-chemotherapy in patients with advanced NS-NSCLC, and more clinical trials are warranted to confirm these results.
INTRODUCTION

Lung cancer remains the most common cancer and has been the main cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers, with most having non-squamous histology. Despite significant improvements have been made in the treatment of advanced NSCLC, The prognosis remains poor with median overall survival (OS) of 8–10 months and 5-year progression-free survival (PFS) of 4%. Currently, the mainstream treatment for advanced non-squamous NSCLC (NS-NSCLC) is to target driver gene mutation such as epidermal growth factor receptor. However, customarily a small fraction of patients were identified as having driver mutations that can benefit from targeted agents. As for patients without sensitive gene mutations, they are unable to benefit from targeted therapy, making the choices of treatment full of passivity for them. Traditional chemotherapy remains the mainstream treatment with a response rate of only 15% ~ 30%.

Bevacizumab is a vascular endothelial growth factor monoclonal antibody, which inhibits angiogenesis to suppress tumor growth by restricting the delivery of oxygen and nutrients to the tumor. Since bevacizumab was added to chemotherapy (Bev-chemotherapy), this combination enhanced treatment efficacy and has become the standard first-line treatment for advanced NS-NSCLC. However, the overall survival (OS) benefit of Bev-chemotherapy remains unsatisfactory.

The introduction of immunotherapy has a howling success, changing the treatment strategy of advanced NS-NSCLC. Immune checkpoint inhibitors (ICIs) of programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors, such as pembrolizumab, nivolumab, and atezolizumab, have been approved for advanced NS-NSCLC because of their substantial improvements in survival compared with chemotherapy. Recently, the IMPower-150 trial showed that first-line ICI plus chemotherapy (ICI-chemotherapy) had survival benefit compared with Bev-chemotherapy in patients with NS-NSCLC. For lack of head-to-head comparison, the safety, efficacy, and prognosis of both combination strategies in first-line treatment remain uncertain. Therefore, we carried out this network meta-analysis (NMA) to determine whether ICI-chemotherapy prolongs survival in advanced untreated NS-NSCLC compared to Bev-chemotherapy.

METHODS

2.1 Data sources and search strategy

We conducted a systematic search from PubMed, Embase, and the Cochrane library up to Sep 1, 2021. We also searched the conference abstracts published at international conferences to identify eligible trials. The search was conducted under the principles outlined in the Cochrane Handbook for Systematic Reviews of Interventions. The search strategies were as follows: (“PD-L1” OR “programmed cell death-1” OR “PD-1” OR “nivolumab” OR “opdivo” OR “pembrolizumab” OR “keytruda” OR “atezolizumab” OR “tecentriq” OR “durvalumab” OR “Imfinzi” OR “avelumab”) OR (“bevacizumab” OR “avastin”) AND (“non-small cell lung” OR “nsclc” OR “lung adenocarcinoma” OR “nonsquamous”) AND (“advanced” OR “metastatic”) AND (“chemotherapy” OR “carboplatin” OR “cisplatin” OR “paclitaxel” OR “docetaxel” OR “pemetrexed”) AND (“first-line” OR “untreated” OR “treatment naïve” OR “chemo naïve” OR “front line”) AND (“controlled clinical trial” OR “RCT” OR “randomly” OR “trial”). The detailed strategies are shown in Supplement 1.

2.2 Inclusion and exclusion criteria

Studies were included as follows: (1) patients had histologically confirmed with advanced NS-NSCLC (stage IIIB-IV); (2) studies involved the comparisons among ICI-chemotherapy, Bev-chemotherapy, and chemotherapy in first-line treatment; (3) study outcomes included objective response rate (ORR), PFS, OS, or grade ≥ 3 treatment-related adverse events (TRAEs); (4) study designs were controlled clinical trials (RCTs). Studies were excluded as follows: (1) studies with duplicate publications; (2) study protocols, reviews, meta-analyses, letters, or case reports; (3) studies with data unavailable. If the trial compared one drug of two different dosages, we chose the usual drug dosage. This NMA was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
2.3 | Outcome measures

The following outcomes were used for analysis: ORR, PFS, OS, and grade ≥ 3 TRAEs. ORR was calculated by the proportion of complete and partial recession. PFS was defined as the time between randomization and disease progression or death from any cause. OS was calculated as the time in between randomization and death from any cause. Grade ≥ 3 TRAEs were evaluated by the common terminology criteria for adverse events. Hazard ratio (HR) with 95% confidence interval (CI) was calculated for continuous variable analysis (OS and PFS), and odds ratio (OR) with 95%CI were estimated for binary variable analysis (ORR and grade ≥ 3 TRAEs).

2.4 | Study selection and data extraction

Two investigators (Z.B. Zhang and Y. Wang) independently screened the studies by title, abstract, and full text based on inclusion and exclusion criteria; any discrepancies were discussed by a third reviewer (J.L. Wang). The extracted data included the first author, publication year, trial name, trial phase, sex, age, smoking history, treatment strategy, drug dose, number of patients, Eastern Cooperative Oncology Group Performance Status (ECOG PS), and the outcomes of OS, PFS, ORR, and grade ≥ 3 TRAEs.

2.5 | Quality assessment

The quality of each included study was assessed by another two reviewers (J.Y. Lu and X.W. Ge) independently with the Cochrane Risk of Bias Tools, including six domains: (1) randomization sequence generation and allocation concealment; (2) blinding of patients and personnel; (3) blinding of outcome assessment; (4) incomplete outcome data; (5) selective outcome reporting; (6) other bias. Discrepancies were mediated by a third investigator (J.L. Wang) and resolved by consensus. Quality assessments for each trial are available in Supplement 2.

2.6 | Statistical analysis

2.6.1 | Pairwise meta-analysis

STATA software (version 15.0) was used for performing pairwise meta-analysis (PMA) in a random-effect model. The I-square was calculated for assessing the extent of variability attributable to heterogeneity between two studies. PMA between ICI-chemotherapy and chemotherapy was conducted stratified by PD-L1 expression, liver metastases, and brain metastases.

2.6.2 | Network meta-analysis

R software (version 4.1.0) with gemtc package (version 1.0) was applied for conducting Bayesian network meta-analysis (NMA) in a random-effect model. Four chains were generated and 100,000 iterations with 10,000 burn-ins for each chain (the interval of 10). R software was also used for identifying the probability of each treatment to be ranked the best for four endpoints and the surface under the cumulative ranking curves (SUCRAs) were presented in ranking plots. Network plots showed the connection between eligible trails based on the number of trails and sample size. The comparison-adjusted funnel plots tested publication bias. To ensure the reliability of NMA, sensitive analysis was conducted by excluding 1 trial with phase II and 3 trials with a sample size of each group less than 100. Inconsistency was assessed by comparing the synthesized HRs of PMA and NMA results. Node splitting analysis was used for assessing the consistency of direct and indirect evidence. The contribution plot was used to measure the percent contribution of direct comparison to the indirect, mixed, and the entire network estimates (Supplementary materials). All tests were two-sided, and a p-value below 0.05 was considered statistically significant.

3 | RESULTS

3.1 | Eligible studies and characteristics

All 2284 records were identified from the databases and international conferences. After screening titles and abstracts to exclude duplicate articles and articles that did not meet the inclusion criteria, 15 eligible RCTs (17 articles) with 6541 advanced NS-NSCLC patients receiving three treatments (ICI-chemotherapy, Bev-chemotherapy, and chemotherapy) were included in this NMA. Seven trials compared Bev-chemotherapy with chemotherapy, seven trials compared ICI-chemotherapy with chemotherapy, and one trial compared ICI-chemotherapy with Bev-chemotherapy (Figure 1). Overall, ICI-chemotherapy, Bev-chemotherapy, and chemotherapy were administered to 2328, 1720, and 2513 patients, respectively. Network plots of all eligible trials were shown in Figure 2. Of all 15 trials, 15 reported ORR and PFS, 14 reported OS, and 11 reported grade ≥ 3 TRAEs. Thirteen of 15 trials were phase III RCTs; 12 of 15 RCTs included more than 100 patients in each arm. Eligible studies and patients' characteristics (Table 1 and Table 2) included the first author, publication...
year, trial name, trial phase, treatment drug, number of patients, sex, age, stage, smoking status, ECOG PS, brain metastases, and liver metastases. Supplement 2 showed that 20.0% (3/15) were high-quality studies and 46.7% (7/15) were accompanied by a high risk of bias for lacking personnel blinding according to the Cochrane Collaboration tool.

3.2 | NMA of outcomes

As listed in Table 3, four outcomes were evaluated by NMA. For OS, the pooled results showed that ICI-chemotherapy (HR 0.68, 95% CI: 0.59–0.78) or Bev-chemotherapy (HR 0.86, 95% CI: 0.75–0.99) improved
| Author (year) Trial | Experimental Arm (E) | Control Arm (C) | Phase | Histology | Patients E/C | PFS (HR 95%CI) | OS (HR 95%CI) | ORR (%) | TRAEs (%) |
|---------------------|---------------------|----------------|-------|-----------|--------------|---------------|---------------|--------|-----------|
| Bev-chemo versus Chemo |                     |                |       |           |              |               |               |        |           |
| Sandler et al. (2006) ECOG4599 | Bev + Paclitaxel + Carboplatin | Paclitaxel + Carboplatin | III   | NS-NSCLC  | 417/433      | 0.66 (0.57, 0.77) | 0.79 (0.67, 0.92) | 34.9/15.1 | 60.9/24.3 |
| Reck et al. (2010) AVAi16 | Bev + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin + Placebo | III   | NS-NSCLC  | 351/347      | 0.82 (0.68, 0.98) | 1.03 (0.86, 1.23) | 30.4/20.1 | 80.5/75.2 |
| Niho et al. (2012) JO1990717 | Bev + Gemcitabine + Cisplatin | Gemcitabine + Cisplatin | II    | NS-NSCLC  | 121/59       | 0.61 (0.42, 0.89) | 0.99 (0.65, 1.50) | NA      | NA        |
| Boutsikou et al. (2013) | Bev + Docetaxel + Carboplatin | Docetaxel + Carboplatin | III   | NS-NSCLC  | 56/61        | 0.37 (0.32, 0.51) | 0.77 (0.38, 1.6) | 39/31   | NA        |
| Galetta et al. (2015) ERACLE19 | Bev + Paclitaxel + Carboplatin | Pemetrexed + Cisplatin | III   | NS-NSCLC  | 58/60        | 0.79 (0.53, 1.17) | 0.93 (0.6, 1.42) | 51.7/40.0 | NA        |
| Zinner et al. (2015) PRONOUNCE20 | Bev + Paclitaxel + Carboplatin | Pemetrexed + Carboplatin | III   | NS-NSCLC  | 179/182      | 0.94 (0.74, 1.19) | 0.93 (0.74, 1.20) | 27.4/23.6 | NA        |
| Zhou et al. (2015) BEYOND21 | Bev + Paclitaxel + Carboplatin | Paclitaxel + Carboplatin + Placebo | III   | NS-NSCLC  | 138/138      | 0.40 (0.29, 0.54) | 0.68 (0.50, 0.93) | 53.6/25.4 | 67.1/61.9 |
| ICI-chemo versus Chemo |                     |                |       |           |              |               |               |        |           |
| West et al. (2019) IMpower-13023 | Atezo + Nabpaclitaxel + Carboplatin | Nabpaclitaxel + Carboplatin | III   | NS-NSCLC without EGFR or ALK mutation | 483/241       | 0.64 (0.54, 0.77) | 0.79 (0.64, 0.98) | 49.2/31.9 | 74.8/60.8 |
| Gadgeel et al. (2020) KEYNOTE-18926 | Pembro + Pemetrexed + Cisplatin | Pemetrexed + Cisplatin | III   | NS-NSCLC without EGFR or ALK mutation | 410/206       | 0.48 (0.40, 0.58) | 0.56 (0.45, 0.70) | 47.6/18.9 | 71.9/66.8 |
| Zhou et al. (2021) CameL24,30 | Camrelizumab + Pemetrexed + Carboplatin | Pemetrexed + Carboplatin + Placebo | III   | NS-NSCLC without EGFR or ALK mutation | 193/196       | 0.37 (0.29, 0.47) | 0.55 (0.40, 0.75) | 64.8/36.7 | 73.6/71.9 |
| Awad et al. (2021) KEYNOTE-02115 | Pembro + Pemetrexed + Carboplatin | Pemetrexed + Carboplatin | II    | NS-NSCLC without EGFR or ALK mutation | 60/63         | 0.54 (0.35, 0.83) | 0.71 (0.45, 1.12) | 63.6/40.0 | 39.0/30.6 |
| Lu et al. (2021) RATIONALE-30427 | Tislelizumab + Platinum + Pemetrexed | Platinum + Pemetrexed | III   | NS-NSCLC without EGFR or ALK mutation | 222/110       | 0.56 (0.41, 0.77) | NA | 57.4/36.9 | 67.6/53.6 |
| Nishio et al. (2021) IMpower-13228 | Atezo + Pemetrexed + Carboplatin or Cisplatin | Pemetrexed + Carboplatin or Cisplatin | III   | NS-NSCLC without EGFR or ALK mutation | 292/286       | 0.60 (0.49, 0.72) | 0.81 (0.64, 1.03) | 47/32 | 54.6/40.1 |

(Continues)
OS compared with chemotherapy. ICI-chemotherapy was associated with better OS than Bev-chemotherapy (HR 0.79, 95%CI: 0.66–0.94). For PFS, the addition of ICI (HR 0.52, 95% CI: 0.42–0.65) or bevacizumab (HR 0.62, 95%CI: 0.50–0.78) to chemotherapy decreased the risk of disease progression, but there were no statistical differences in PFS between ICI-chemotherapy and Bev-chemotherapy ($p > 0.05$). For ORR, patients with either ICI-chemotherapy (OR 1.7, 95% CI: 1.0–2.0) or Bev-chemotherapy (OR 1.4, 95% CI: 1.0–1.9) had more grade ≥ 3 TRAEs than chemotherapy, while no statistical differences were identified between ICI-chemotherapy and Bev-chemotherapy ($p > 0.05$).

### 3.3 | Treatment ranking

The treatment ranking plots for four outcomes were shown in Figure 3, which suggested that ICI-chemotherapy had the most probability to offer the best OS (probability 0.993), PFS (probability 0.658), ORR (probability 0.565), and Bev-chemotherapy had the most risks of grade ≥ 3 TRAEs (probability 0.833).

### 3.4 | Subgroup analysis

Subgroup PMA was conducted for comparing ICI-chemotherapy with chemotherapy. Stratified by PD-L1 expression, patients with PD-L1 ≥ 1% (HR 0.42, 95%CI: 0.33–0.53) or PD-L1 < 1% (HR 0.58, 95%CI: 0.45–0.74) had PFS benefit, while only patients with PD-L1 ≥ 1% (HR 0.59, 95%CI: 0.46–0.76) had OS benefit. Stratified by liver metastases, ICI-chemotherapy was associated with longer PFS in patients with liver metastases (HR 0.70, 95%CI: 0.54–0.91) or no liver metastases (HR 0.56, 95%CI: 0.49–0.65) compared with chemotherapy, while OS benefit only existed in patients with no liver metastases (HR 0.72, 95%CI: 0.57–0.90). Stratified by brain metastases, ICI-chemotherapy was in association with better PFS and OS for patients with no brain metastases (PFS: HR 0.44, 95%CI: 0.31–0.64; OS: HR 0.46, 95%CI: 0.30–0.70) or brain metastases (PFS: HR 0.48, 95%CI: 0.41–0.57; OS: HR 0.59, 95%CI: 0.49–0.72) than chemotherapy (Figure 4).

Subgroup NMA was performed in patients with liver metastases, including one trial comparing ICI-chemotherapy with Bev-chemotherapy, three trials comparing ICI-chemotherapy with chemotherapy, and one
| No. | Trial          | Experimental Arm (E) | Control Arm (C) | Patients | Male | Age (median) | Stage IV | Smokers | ECOG = 0 | Brain metastases | Liver metastases |
|-----|----------------|----------------------|-----------------|----------|------|--------------|----------|---------|----------|------------------|-----------------|
| 1   | ECOG4599       | Bev-chemo            | Chemo           | 417/433  | 50/58| 56/58        | 74/78    | —       | 40/40    | —                | 22/17           |
| 2   | AVAIL          | Bev-chemo            | Chemo           | 351/347  | 62/64| 59/59        | 77/77    | —       | 41/41    | —                | —               |
| 3   | JO19907        | Bev-chemo            | Chemo           | 121/59   | 64/64| 56/57        | 69/71    | 69/68   | 51/49    | —                | —               |
| 4   | Boutsikou 2013 | Bev-chemo            | Chemo           | 56/61    | 80/85| 63/65        | 73/84    | 84/87   | —        | —                | —               |
| 5   | ERACLE         | Bev-chemo            | Chemo           | 58/60    | 78/70| 62/60        | 93/95    | 60/70   | 79/78    | —                | —               |
| 6   | BEYOND         | Bev-chemo            | Chemo           | 138/138  | 54/56| 57/56        | 91/91    | 50/44   | 25/20    | —                | —               |
| 7   | PRONOUNCE      | Bev-chemo            | Chemo           | 179/182  | 58/58| 65/66        | 100/99.5 | 96/90   | 46.9/46.7 | 12.6/17.9       | —               |
| 8   | IMpower-132    | ICI-chemo            | Chemo           | 292/286  | 66/67| 64/63        | 100/100  | 87.3/89.5| 43.2/40.1 | —                | 12.7/12.6       |
| 9   | IMpower-130    | ICI-chemo            | Chemo           | 483/241  | 59/59| 64/65        | 100/100  | 89/93   | 42/40    | —                | 15/14           |
| 10  | CameL          | ICI-chemo            | Chemo           | 193/196  | 71/72| 59/61        | 85/80    | 62/63   | 23/17    | 5/2              | —               |
| 11  | RATIONALE-304  | ICI-chemo            | Chemo           | 222/110  | 75.3/71.2| 60/61      | 82.1/81.1| 65.9/59.4| 24.2/21.6| 4.9/6.3          | 9.0/15.3        |
| 12  | KEYNOTE-021    | ICI-chemo            | Chemo           | 60/63    | 37/41| 63/66        | 98/95    | 75/86   | 40/46    | 20/11            | —               |
| 13  | ORIENT-11      | ICI-chemo            | Chemo           | 266/131  | 76.7/75.6| 61/61      | 92.1/88.5| 64/66   | 29/26    | 13.5/16.8        | —               |
| 14  | KEYNOTE-189    | ICI-chemo            | Chemo           | 410/206  | 62/53| 65/64        | 100/100  | 88/88   | 45/39    | 17.8/17.0        | 16.1/23.8       |
| 15  | IMpower-150    | ICI-chemo            | Bev-chemo       | 402/400  | 60/60| 63/63        | 100/100  | 81/81   | 44.8/40.1 | —                | 13/14           |
### Table 3  Network meta-analysis of clinical outcomes

|                | HR for OS          | OR for ORR   | HR for PFS | OR for TRAEs ≥ 3 |
|----------------|--------------------|--------------|------------|------------------|
|                | ICI-chemo          | Bev-chemo    | Bev-chemo  | Bev-chemo        |
| 0.79 (0.66, 0.94) | 0.76 (0.66, 0.94)  | 0.88 (0.75, 0.99) | 0.84 (0.63, 1.10) | 0.86 (0.75, 0.99) |
| 0.68 (0.59, 0.78) | 0.86 (0.59, 0.78)  | 0.52 (0.42, 0.65) | 0.62 (0.50, 0.78) | 0.62 (0.50, 0.78) |
| OR for ORR      |                    |              |            |                  |
| ICI-chemo       | 1.0 (0.8, 1.3)     | 1.7 (1.5, 2.0) | 1.2 (0.9, 1.5) | 1.4 (1.0, 1.9)   |
| Bev-chemo       | 0.9 (0.6, 1.2)     | 1.7 (1.4, 2.0) | 1.2 (0.9, 1.5) | 1.4 (1.0, 1.9)   |
| Chemo           |                    |              |            |                  |

Abbreviations: bev, bevacizumab; chemo, chemotherapy; HR, hazard ratio; ICI, immune checkpoint inhibitor; OR, odds ratio; objective response rate; OS, overall survival; PFS, progression-free survival; TRAEs, treatment-related adverse events.

![Treatment ranking plot](image-url)
trial comparing Bev-chemotherapy with chemotherapy (Supplement 3). The results demonstrated that there were no significant differences in PFS and OS among three treatments (ICI-chemotherapy, Bev-chemotherapy, and chemotherapy) in patients with liver metastases ($P > 0.05$) (Supplement 4).

3.5 | Heterogeneity and publication bias

Heterogeneity was evaluated in direct, indirect, and network comparations. The results showed that there was little heterogeneity among included trials with $I^2 > 50\%$ (Supplement 5). Comparison-adjusted funnel plots were
presented in Supplement 6, which indicated little publication bias among included trials.

3.6 | Inconsistency assessment

The inconsistency assessment was performed using node-splitting analysis for OS, PFS, ORR, and grade $\geq 3$ TRAEs, the results showed the consistency among direct, indirect, and network comparisons with all $p > 0.05$. Forest plots of direct, indirect, and network comparisons were generated for OS, PFS, ORR, and grade $\geq 3$ TRAEs (Figure 5).

3.7 | Sensitivity analysis and contribution of direct comparison

As shown in Supplement 7, we excluded one trial with phase II and three trials with a sample size of less than 100 in each group. A total of 11 trials, involving 6023 previous untreated NS-NSCLC patients, were enrolled in the sensitivity analysis. The results were similar to the main analysis. Therefore, we included all trials for the robustness of the final NMA results. The contribution plots of direct comparison are presented in Supplement 8.

4 | DISCUSSION

Immune checkpoint inhibitors (ICIs) have been noted to show promise for cancer treatment due to their advances in cancer treatments and have been clinically approved in a variety of malignancies. PD-1, an essential regulator of adaptive immune responses, is primarily involved in immune inhibitory signaling and is ectopically expressed on antitumor T cells, while expression of its ligand PD-L1 can be upregulated by tumor cells and block antitumor effects. PD-1/PD-L1 inhibitors could abolish this suppression effect and reactivate the antitumor effect of T cells. Blocking the PD-1/PD-L1 pathway has emerged as a front-line treatment strategy for various cancers, in particular NSCLC. Unlike chemotherapy, blocking immune checkpoint could indirectly

**FIGURE 5** Forest plots for direct, indirect, and network meta-analysis (NMA). 1: ICI-chemotherapy, 2: Bev-chemotherapy, 3: Chemotherapy. PFS, progression-free survival; OS, overall survival; ORR, objective response rate; TRAEs, treatment-related adverse events; ICI, immune checkpoint inhibitor; bev, bevacizumab; chemo, chemotherapy
target tumors by boosting antitumor immune responses and these effects have been reported to be durable in a subset of patients.48

Conventional chemotherapy is the main treatment option for NS-NSCLC patients.49 The combination of ICIs and chemotherapy have higher efficacy compared to chemotherapy and is therefore recommended by NCCN guidelines as first-line treatment of advanced NS-NSCLC.50,51 Currently, ICI-chemotherapy has emerged as a new treatment option on advanced NS-NSCLC patients without the driver gene mutation. Bevacizumab, a monoclonal antibody against VEGFR, is beneficial in combination with chemotherapy for advanced NS-NSCLC, and Bev-chemotherapy has been the standard treatment for advanced NS-NSCLC. IMpower-150 trial was the first RCT comparing ICI-chemotherapy with Bev-chemotherapy in previous untreated NS-NSCLC patients with advanced-stage, the results showed that patients with ICI-chemotherapy had prolonged survival compared with those with Bev-chemotherapy.35 The comparison between first-line ICI-chemotherapy and Bev-chemotherapy in advanced NS-NSCLC remains unclear due to the lack of direct comparisons between ICI-chemotherapy and Bev-chemotherapy. Therefore, we performed this NMA to compare the potential of these two combination strategies.

We initially performed NMA among ICI-chemotherapy, Bev-chemotherapy, and chemotherapy for previously untreated patients with advanced NS-NSCLC. Based on 15 RCTs, the results indicated an OS benefit with ICI-chemotherapy compared to Bev-chemotherapy, while no differences were observed on ORR, PFS, and grade ≥ 3 TRAEs. Treatment ranking plots revealed that ICI-chemotherapy was most likely to deliver the best OS, PFS, and highest risk of TRAEs ≥3, while Bev-chemotherapy had the highest ORR. Furthermore, we performed subgroup NMA in patients with liver metastases, and no differences in PFS and OS were detected between ICI-chemotherapy and Bev-chemotherapy. Our findings demonstrated that first-line ICI-chemotherapy was associated with better OS than Bev-chemotherapy in advanced EC patients except for those with liver metastases. A comparison between ICI-chemotherapy and Bev-chemotherapy stratified by biomarkers such as PD-L1 expression was not performed due to the unavailability of data, which requires further investigation.

There were several limitations in this study. First, different PD-1/PD-L1 inhibitors (pembrolizumab, camrelizumab, tislelizumab, and sintilimab) and chemotherapy regimens were used in different RCTs, which may have affected the final results. Second, the genetic status in Bev-chemotherapy trials was unknown, whereas immunotherapy trials involved patients without the driver gene mutation. Third, some trials allowed patients to cross over from chemotherapy to ICI-chemotherapy after progressions such as the KEYNOTE-021 trial and CameL trial, which may decrease the OS benefit of ICI-chemotherapy. Fourth, heterogeneity and publication bias existed, several trials are still ongoing with incomplete data, we thus conducted sensitive analysis and the results were consistent with the main analysis. Lastly, due to the unavailability of data, we only performed a subgroup NMA stratified by liver metastases. Despite the above limitations, our study still confirmed the favorable survival of ICI-chemotherapy versus Bev-chemotherapy without more severe TRAEs.

5 | CONCLUSION

This study elucidates that ICI-chemotherapy is superior to Bev-chemotherapy for improved OS in first-line treatment of advanced NS-NSCLC. More clinical trials are warranted to confirm these results.

ACKNOWLEDGMENTS

This study was approved by the Ethics Committee of Chinese PLA General Hospital, and the protocol was registered in PROSPERO International Prospective Register of Systematic Reviews (CRD42020212984).

CONFLICT OF INTEREST

All authors declare that there is no conflict of interest.

AUTHOR CONTRIBUTIONS

J.L. Wang and Y. Hu conceived and designed the research. Data collection and extraction were performed by Z.B. Zhang and verified by Y. Wang. Statistical analysis was performed by Z.B. Zhang and Y. Wang. All authors participated in drafting and revising this article and gave final approval to the version submitted.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID

Jinzhao Zhai https://orcid.org/0000-0002-6068-6185
Zhibo Zhang https://orcid.org/0000-0001-8534-7190
Xiaoyu Zhi https://orcid.org/0000-0003-0883-2664
Di Lu https://orcid.org/0000-0003-1040-7763

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442
2. Hong QY, Wu GM, Qian GS, et al. Prevention and management of lung cancer in China. Cancer. 2015;121(Suppl 17):3080-3088. doi: 10.1002/cncr.29584
3. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013

4. Cetin K, Ettinger DS, Hei YJ, O’Malley CD. Survival by histologic subtype in stage IV non-small cell lung cancer based on data from the surveillance, epidemiology and end results program. Clin Epidemiol. 2011;3:139-148. doi: 10.2147/clep.S17191

5. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM staging groups in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009

6. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.

7. Thomas JL, Daphne WB, Raffaella S, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(350):2129-2139. doi: 10.1056/NEJMoa040938

8. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive adenocarcinoma (LUX- lung 3 and LUX- lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-151. doi: 10.1016/s1470-2045(14)71173-8

9. Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP. Analysis of EGFR, EML4- ALK, KRAS, and c-MET mutations in lung adenocarcinoma patients. Exp Lung Res. 2013;39(8):328-335. doi: 10.1080/01902148.2013.819535

10. Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877-1883. doi: 10.1093/annonc/mdv276

11. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin[R]) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi: 10.1016/j.ctrv.2020.102017

12. Midgley R, Kerr D. Bevacizumab–current status and future directions. Ann Oncol. 2005;16(7):999-1004. doi: 10.1093/annonc/mdi208

13. Castro D, Gonzalez-Larriba JL, Vazquez S, et al. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. Clin Transl Oncol. 2017;19:219-226. doi: 10.1007/s12094-016-1527-8

14. Crino L, Dansin E, Garrido P, Griesinger F, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAIL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):703-704. doi: 10.1016/S1470-2045(10)70151-0

15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550. doi: 10.1056/NEJMoa061884

16. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAIL). Ann Oncol. 2010;21(9):1804-1809. doi: 10.1093/annonc/mdq020

17. Niho S, Kunitoh H, Nokihara H, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76(3):362-367. doi: 10.1016/j.lungcan.2011.12.005

18. Boutsikou E, Kontakiotis T, Zarogoulidis P, et al. Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Oncotargets Ther. 2013;6:125-134. doi: 10.2147/ott.S42245

19. Galetta D, Cinieri S, Pisconti S, et al. Cisplatin/pemetrexed followed by maintenance pemetrexed versus carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (Gruppo Oncologico Italico Meridionale) ERACLE phase III randomized trial. Clin Lung Cancer. 2015;16(4):262-273. doi: 10.1016/j.clincancer.2014.12.002

20. Zinner RG, Obasaju CK, Spigel DR, et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed+carboplatin followed by maintenance pemetrexed versus paclitaxel+carboplatin+bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015;10(1):134-142. doi: 10.1097/jto.0000000000000366

21. Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197-2204. doi: 10.1200/jco.2014.59.4424

22. Reck M, Pawel JV, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAIL. J Clin Oncol. 2009;27(8):1227-1234. doi: 10.1200/jco.2007.14.5466

23. West H, McLeod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924-937. doi: 10.1016/s1470-2045(19)30167-6

24. Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2020;9(3):305-314. doi: 10.1016/s2213-2600(20)30365-9

25. Awad MM, Gadgeel SM, Borghaei H, et al. Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol. 2021;16(1):162-168. doi: 10.1016/j.jtho.2020.09.015

26. Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic non–small-cell lung cancer. J Clin Oncol. 2020;38(14):1505-1517. doi: 10.1200/jco.19.03136

27. Lu S, Wang J, Yu Y, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic non-squamous NSCLC (RATIONALE 304): a randomized phase
3 trial. J Thorac Oncol. 2021;16(9):1512-1522. doi: 10.1016/j.jtho.2021.05.005

28. Nishio M, Barlesi F, West H, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the phase 3 IMpower112 trial. J Thorac Oncol. 2021;16(4):653-664. doi: 10.1016/j.jtho.2020.11.025

29. Yang Y, Sun J, Wang Z, et al. Updated overall survival data and predictive biomarkers of Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J Thorac Oncol. 2021;16(12):2109-2120. doi: 10.1016/j.jtho.2021.07.015

30. Zhou C, Ren S, Chen J, et al. Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (Camel-sq): a randomized, double-blind, multicenter, phase III trial. J Thorac Oncol. 2021;16(suppl_4):S748-S802. doi: 10.1016/S1556-0864(21)01938-9

31. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135. doi: 10.1056/NEJMoA1507643

32. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7

33. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre, randomised controlled trial. Lancet. 2017;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X

34. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833. doi: 10.1056/NEJMoa1606774

35. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for Atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909-1924. doi: 10.1016/j.jtho.2021.07.009

36. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower163): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387-401. doi: 10.1016/s2213-2600(19)30084-0

37. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-1012. doi: 10.1016/j.jclinepi.2009.06.005

38. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903-909. doi: 10.1016/s1470-2045(06)70910-x

39. Higgins JPT, Altman DG, Gitzche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928

40. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139-145. doi: 10.1016/j.cct.2015.09.002

41. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.

42. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. doi: 10.1136/bmj.315.7109.629

43. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7-8):932-944. doi: 10.1002/sim.3767

44. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. doi: 10.1056/NEJMoa1003466

45. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34. doi: 10.1056/NEJMoa1504030

46. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-1356. doi: 10.1056/NEJMoa1709684

47. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355. doi: 10.1126/science.aar4060

48. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86. doi: 10.3389/fonc.2018.00086

49. Hanna NH, Schneider BJ, Temin S, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2020;38(14):1608-1632. doi: 10.1200/jco.19.03022

50. Ettinger DS, Wood DE, Aggarwal C, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw. 2020;18(4):406-422. doi: 10.6004/jnccn.2020.0055

51. Rubens MA, Davies M. NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer. J Natl Compr Canc Netw. 2019;17(5):574-578. doi: 10.6004/jnccn.2019.5005

**SUPPORTING INFORMATION**
Additional supporting information may be found in the online version of the article at the publisher’s website.

---

**How to cite this article:** Zhai J, Lu J, Zhang Z. First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials. Cancer Med. 2022;11:2043–2055. doi: 10.1002/cam.4.4589